Nectar Lifesciences Ltd
NSE:NECLIFE
Nectar Lifesciences Ltd
NSE:NECLIFE
Price:
11.75
INR
9.92%
Market Closed
Market Cap:
₹2.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Nectar Lifesciences Ltd
NSE:NECLIFE
|
IN |
|
B
|
Berjaya Philippines Inc
XPHS:BCOR
|
PH |
|
Pegasus Sewing Machine Mfg Co Ltd
TSE:6262
|
JP |
|
DMK Pharmaceuticals Corp
OTC:DMKPQ
|
US |
|
MFA Financial Inc
NYSE:MFA
|
US |
|
Karsu Tekstil Sanayi ve Ticaret AS
IST:KRTEK.E
|
TR |
|
Manila Electric Co
XPHS:MER
|
PH |
|
C
|
Cibus Inc
NASDAQ:CBUS
|
US |
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
TW |
|
Z
|
Zillow Group Inc
NASDAQ:Z
|
US |
|
Renasant Corp
NYSE:RNST
|
US |
|
9
|
908 Devices Inc.
NASDAQ:MASS
|
US |
|
Anadolu Efes Biracilik ve Malt Sanayii AS
OTC:AEBZY
|
TR |
Multiples-Based Value
The Multiples-Based Value of one
NECLIFE
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 11.75 INR,
Nectar Lifesciences Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NECLIFE Multiples-Based Value
LOCKED
Multiples Across Competitors
NECLIFE Competitors Multiples
Nectar Lifesciences Ltd Competitors
Nectar Lifesciences Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Nectar Lifesciences Ltd
NSE:NECLIFE
|
2.6B INR | 0.4 | -0.7 | -1.3 | -1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.4 | 42.5 | 28.7 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.5 | 11.6 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.5B GBP | 5.2 | 30.1 | 16.6 | 23.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.2 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF | 5.2 | 20.8 | 12.9 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.4B GBP | 2.7 | 15.5 | 8.4 | 10.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
